Deficiency of Tfh Cells and Germinal Center in Deceased COVID-19 Patients

Abstract

The COVID-19 pandemic caused by SARS-CoV2 is characterized by a remarkable variation in clinical severity ranging from a mild illness to a fatal multi-organ disease. Understanding the dysregulated human immune responses in the fatal subjects is critical for management of COVID-19 patients and the pandemic. In this study, we examined the immune cell compositions in the lung tissues and hilar lymph nodes using immunohistochemistry on 6 deceased COVID-19 patients and 4 focal organizing pneumonia (FOP) patients who underwent lung surgery and served as controls. We found a dominant presence of macrophages and a general deficiency of T cells and B cells in the lung tissues from deceased COVID-19 patients. In contrast to the FOP patients, Tfh cells and germinal center formation were largely absent in the draining hilar lymph nodes in the deceased COVID-19 patients. This was correlated with reduced IgM and IgG levels compared to convalescent COVID-19 patients. In summary, our data highlight a defect of germinal center structure in deceased COVID-19 patients leading to an impaired humoral immunity. Understanding the mechanisms of this deficiency will be one of the key points for the management of this epidemic.

Keywords

COVID-19 / immune responses / germinal center / T follicular helper cells

References

[1] HuangC, WangY, LiX, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020, 395: 497-506

[2] Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med, 2020, NEJMc2011400

[3] LiW, MooreMJ, VasilievaN, et al.. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 2003, 426: 450-4

[4] ShangJ, YeG, ShiK, et al.. Structural basis of receptor recognition by SARS-CoV-2. Nature, 2020, 581: 221-224

[5] WangD, HuB, HuC, et al.. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama, 2020, 323: 1061-9

[6] XuX, HanM, LiT, et al.. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A, 2020, 117: 10970-10975

[7] Giamarellos-BourboulisEJ, NeteaMG, RovinaN, et al.. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe, 2020, 27: 992-1000.e3

[8] XuZ, ShiL, WangY, et al.. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020, 8: 420-422

[9] Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis, 2020, ciaa248

[10] MesinL, ErschingJ, VictoraGD. Germinal Center B Cell Dynamics. Immunity, 2016, 45: 471-482

[11] CysterJG, AllenCDC. B Cell Responses: Cell Interaction Dynamics and Decisions. Cell, 2019, 177: 524-540

[12] ThevarajanI, NguyenTHO, KoutsakosM, et al.. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med, 2020, 26: 453-455

[13] NiL, YeF, ChengML, et al.. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity, 2020, 52(6): 971-977.e3

[14] CaoY, SuB, GuoX, et al.. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell, 2020, 182(1): 73-84.e16

[15] DiaoB, WangC, TanY, et al.. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). Front Immunol, 2020, 11: 827

[16] TanL, WangQ, ZhangD, et al.. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduc Target Ther, 2020, 5(1): 33

[17] ChenG, WuD, GuoW, et al.. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest, 2020, 130: 2620-2629

[18] CrottyS. Follicular Helper CD4 T Cells (TFH). Annu Rev Immunol, 2011, 29: 621-663

[19] GrifoniA, WeiskopfD, RamirezSI, et al.. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 2020, 181(7): 1489-1501.e15